1.Carcinoma buccal mucosa treated with definitive hypofractionated accelerated radiotherapy: a retrospective analysis of treatment outcomes.
Geethu BABU ; Rejnish RAVIKUMAR ; Malu RAFI ; Zuzaki SHARAFUDDIN ; Arun SHANKAR S ; Preethi Sara GEORGE ; Cessal Thommachan KAINICKAL ; Ramadas KUNNAMBATH
Singapore medical journal 2025;66(7):368-372
INTRODUCTION:
Oral cancer is a major public health concern in India. Both conventional and altered fractionation radiotherapy schedules have been used in curative treatment of oral cancer. This study aimed to retrospectively evaluate the clinical profile and treatment outcomes of patients with carcinoma buccal mucosa who underwent treatment with definitive hypofractionated accelerated radiotherapy.
METHODS:
A total of 517 patients treated from January 2011 to December 2016 were eligible for the analysis. All patients were treated with definitive hypofractionated accelerated radiotherapy schedule of 5,250 cGy in 15 fractions over 3 weeks. Survival estimates were generated using the Kaplan-Meier method.
RESULTS:
At a median follow-up of 77.4 months, 473 (91.5%) patients attained complete remission with radiation therapy. The 5-year disease-free survival (DFS) and overall survival (OS) rates were 69% and 80.5%, respectively. The 5-year OS for stage I, II, III and IVa tumours was 80.3%, 84.4%, 81.4% and 73.7%, respectively, and the DFS was 75.7%, 73.2%, 69.6% and 60.2%, respectively. Age >50 years was found to be a significant factor affecting DFS ( P = 0.026) and OS ( P = 0.048) in multivariate analysis. Fifty-three (10.3%) patients developed osteoradionecrosis of the mandible.
CONCLUSION
Excellent outcome could be achieved in less-aggressive, low-volume carcinoma of the buccal mucosa with radical accelerated hypofractionated radiotherapy. A radiotherapy schedule over a 3-week period is useful in high-volume centres.
Humans
;
Retrospective Studies
;
Male
;
Female
;
Middle Aged
;
Mouth Neoplasms/mortality*
;
Mouth Mucosa/radiation effects*
;
Treatment Outcome
;
Aged
;
Adult
;
Radiation Dose Hypofractionation
;
Disease-Free Survival
;
India
;
Kaplan-Meier Estimate
;
Dose Fractionation, Radiation
;
Aged, 80 and over
2.Precision therapy targeting CAMK2 to overcome resistance to EGFR inhibitors in FAT1 -mutated oral squamous cell carcinoma.
Yumeng LIN ; Yibo HUANG ; Bowen YANG ; You ZHANG ; Ning JI ; Jing LI ; Yu ZHOU ; Ying-Qiang SHEN ; Qianming CHEN
Chinese Medical Journal 2025;138(15):1853-1865
BACKGROUND:
Oral squamous cell carcinoma (OSCC) is a prevalent type of cancer with a high mortality rate in its late stages. One of the major challenges in OSCC treatment is the resistance to epidermal growth factor receptor (EGFR) inhibitors. Therefore, it is imperative to elucidate the mechanism underlying drug resistance and develop appropriate precision therapy strategies to enhance clinical efficacy.
METHODS:
To evaluate the efficacy of the combination of the Ca 2+ /calmodulin-dependent protein kinase II (CAMK2) inhibitor KN93 and EGFR inhibitors, we performed in vitro and in vivo experiments using two FAT atypical cadherin 1 ( FAT1 )-deficient (SCC9 and SCC25) and two FAT1 wild-type (SCC47 and HN12) OSCC cell lines. We assessed the effects of EGFR inhibitors (afatinib or cetuximab), KN93, or their combination on the malignant phenotype of OSCC in vivo and in vitro . The alterations in protein expression levels of members of the EGFR signaling pathway and SRY-box transcription factor 2 (SOX2) were analyzed. Changes in the yes-associated protein 1 (YAP1) protein were characterized. Moreover, we analyzed mitochondrial dysfunction. Besides, the effects of combination therapy on mitochondrial dynamics were also evaluated.
RESULTS:
OSCC with FAT1 mutations exhibited resistance to EGFR inhibitors treatment. The combination of KN93 and EGFR inhibitors significantly inhibited the proliferation, survival, and migration of FAT1 -mutated OSCC cells and suppressed tumor growth in vivo . Mechanistically, combination therapy enhanced the therapeutic sensitivity of FAT1 -mutated OSCC cells to EGFR inhibitors by modulating the EGFR pathway and downregulated tumor stemness-related proteins. Furthermore, combination therapy induced reactive oxygen species (ROS)-mediated mitochondrial dysfunction and disrupted mitochondrial dynamics, ultimately resulting in tumor suppression.
CONCLUSION
Combination therapy with EGFR inhibitors and KN93 could be a novel precision therapeutic strategy and a potential clinical solution for EGFR-resistant OSCC patients with FAT1 mutations.
Humans
;
ErbB Receptors/metabolism*
;
Mouth Neoplasms/metabolism*
;
Cell Line, Tumor
;
Animals
;
Drug Resistance, Neoplasm/genetics*
;
Cadherins/metabolism*
;
Carcinoma, Squamous Cell/metabolism*
;
Mice
;
Mutation/genetics*
;
Mice, Nude
;
Protein Kinase Inhibitors/therapeutic use*
;
Cetuximab/pharmacology*
;
Afatinib/therapeutic use*
;
Cell Proliferation/drug effects*
;
Signal Transduction/drug effects*
3.Clinical study on repair of oral and perioral tissue defects with facial artery perforator myomucosal flap in 8 cases.
Chinese Journal of Reparative and Reconstructive Surgery 2025;39(9):1137-1142
OBJECTIVE:
To explore the technical key points and effectiveness of the facial artery perforator myomucosal flap (FAPMF) in repairing oral and perioral tissue defects.
METHODS:
Between June 2023 and December 2024, 8 patients with oral and perioral tissue defects were repaired with the FAPMF. There were 4 males and 4 females, with an average age of 57.6 years (range, 45-72 years). Among them, 4 cases had floor-of-mouth defects and 3 cases had buccal mucosa defects remaining after squamous cell carcinoma resection, and 1 case had lower lip defect caused by trauma. The size of tissue defects ranged from 4.5 cm×3.0 cm to 6.0 cm×5.0 cm. The preoperative mouth opening was (39.55±1.88) mm, and the preoperative swallowing score of the University of Washington Quality of Life Questionnaire (UW-QOL) was 64.64±8.47. Preoperatively, CT angiography and Doppler ultrasound were used to locate the perforator vessels. A myomucosal flap pedicled with the perioral perforators of the facial artery was designed, with the harvesting size ranging from 4.0 cm×2.5 cm to 6.5 cm×4.0 cm. The length of the vascular pedicle was 4.2-6.8 cm (mean, 5.2 cm). Postoperatively, FAPMF survival, complications, and functional recovery were observed.
RESULTS:
All 8 surgeries were successfully completed without conversion to other repair methods or complications such as facial nerve injury. The total operation time ranged from 110 to 180 minutes, with an average of 142.5 minutes; among this, the harvesting time of the FAPMF ranged from 35 to 65 minutes, with an average of 48.7 minutes. The intraoperative blood loss was 50-150 mL, with an average of 85.6 mL. All FAPMFs survived completely. One patient developed venous reflux disorder at 24 hours after operation, which relieved after conservative treatment. All patients were followed up 7-16 months (mean, 12.4 months). All FAPMFs achieved complete epithelialization at 3 months after operation, showing a similar soft texture to the surrounding mucosa. At 7 months after operation, the mouth opening was (39.11±1.79) mm, slightly lower than preoperative level, but the difference was not significant (P>0.05). The swallowing score of the UW-QOL was 63.78±8.31, which was significantly lower than preoperative score (P<0.05). The visual analogue scale (VAS) score for patient satisfaction was 7-10, with an average of 8.9.
CONCLUSION
The FAPMF has advantages such as reliable blood supply, high mucosal matching degree, and concealed donor site, making it an ideal option for repairing small and medium-sized oral and perioral tissue defects.
Humans
;
Male
;
Middle Aged
;
Female
;
Perforator Flap/blood supply*
;
Aged
;
Plastic Surgery Procedures/methods*
;
Mouth Neoplasms/surgery*
;
Mouth Mucosa/surgery*
;
Mouth/surgery*
;
Quality of Life
;
Face/surgery*
;
Treatment Outcome
;
Carcinoma, Squamous Cell/surgery*
;
Arteries/surgery*
4.Clinical outcomes of partial sialoadenectomy for the treatment of benign tumors in the submandibular gland.
Yuanyuan YANG ; Shanshan ZHANG ; Guangyan YU ; Huijun YANG ; Hongyu YANG
Journal of Peking University(Health Sciences) 2025;57(2):334-339
OBJECTIVE:
To evaluate the clinical outcomes and explore the application of partial sialoadenectomy for the treatment of benign tumors in the submandibular gland (SMG).
METHODS:
Patients with pleomorphic adenoma of the SMG who underwent surgical treatment in the Department of Oral and Maxillofacial Surgery, Peking University Shenzhen Hospital, from October 2017 to February 2021, were enrolled and assessed in the follow-up. Fifteen patients underwent partial sialoadenectomy (PS group), and 18 patients underwent total sialoadenectomy (TS group). Postoperative salivary secretion, degree of dry mouth, appearance changes of the face and neck, nerve damage, and tumor recurrence were compared between the groups. The volume of the glands on the operated and contralateral sides of the patients in the PS group, the saliva flow rate, and their correlations, were also analyzed.
RESULTS:
There was no recurrence during the follow-up period. The whole saliva flow rate at rest in the PS group was higher than that in the TS group [(2.15±1.10) g/5 min vs. (1.35±0.97) g/5 min, t=2.208, P=0.035)], while the stimulated saliva flow rate was not significantly different. The objective feeling of dry mouth, evaluated by visual analogue scale (VAS) score, was more obvious in the TS group than in the PS group (Z=-2.244, P=0.025). In the PS group, the resting saliva flow rate of the SMG on the operated side was lower than that on the contralateral side of the same patient [(0.92±0.40) g/5 min vs. (1.18±0.40) g/5 min, t=-2.821, P=0.014], however, in the cases whose remaining SMG was more than 80% of the contralateral side, the saliva flow rate of both sides was not significantly different (t=-0.027, P=0.980). There was no significant difference in the saliva flow rate per unit volume of the gland on either side (t=-0.015, P=0.989), and the saliva flow rate of the operated SMG was positively correlated with the volume of the remaining gland (r=0.750, P=0.012). The VAS scores for neck deformity were not significantly different between the two groups (t=-0.997, P=0.319). No symptoms of nerve injury occurred in either group.
CONCLUSION
Partial sialoadenectomy in the SMG can safely remove benign tumors while preserving glandular secretory function, with fewer complications and improved quality of life.
Humans
;
Submandibular Gland/pathology*
;
Male
;
Female
;
Middle Aged
;
Adenoma, Pleomorphic/surgery*
;
Adult
;
Treatment Outcome
;
Submandibular Gland Neoplasms/surgery*
;
Saliva/metabolism*
;
Aged
5.Progress of 3D Printing Technology in Resection and Reconstruction of Oral and Maxillofacial Tumors.
Chinese Journal of Medical Instrumentation 2025;49(5):514-519
Oral and maxillofacial tumors, due to their complex anatomical structures and vital physiological functions, pose significant risks, not only affecting patients' appearance and function but also potentially endangering their lives. Traditional tumor resection and reconstruction surgeries face challenges such as inadequate precision, long surgical durations, and unsatisfactory postoperative outcomes. In the treatment of oral and maxillofacial tumors, 3D printing technology can be used for preoperative planning, surgical guide plate production, and the design and manufacture of personalized prosthetics, providing new solutions for functional reconstruction after tumor resection. This article reviews the progress of 3D printing technology in the medical field and explores its potential value in the resection and reconstruction of oral and maxillofacial tumors, aiming to provide references for clinical practice and promote the further application and development of this technology in oral and maxillofacial surgery.
Printing, Three-Dimensional
;
Humans
;
Plastic Surgery Procedures/methods*
;
Mouth Neoplasms/surgery*
6.A rare case report of moderately differentiated adenosquamous carcinoma in the parotid gland associated with IgG4-related disease and literature review.
Huarong PANG ; Qiuping LU ; Zhangmo HUANG ; Jiejun YANG ; Qingyun XIE ; Biru ZHANG
Journal of Clinical Otorhinolaryngology Head and Neck Surgery 2025;39(8):749-753
Objective:To explore the clinical manifestations of IgG4-related diseases(IgG4-RD) complicated with moderately differentiated adenosquamous carcinoma of the parotid gland, the diagnostic criteria for IgG4-related diseases and parotid malignant tumors, treatment regimens, and the application of fine-needle aspiration in disease diagnosis, so as to reduce clinical misdiagnosis and missed diagnosis. Methods:A retrospective analysis was conducted on the case data of a patient with IgG4-related diseases(IgG4-RD) complicated with moderately differentiated adenosquamous carcinoma of the parotid gland admitted to our department in March 2024. The clinical characteristics, imaging findings, preoperative puncture results, and postoperative pathological features were analyzed, and relevant literatures on both diseases were reviewed and summarized. Results:The elderly male patient was admitted due to "a mass in the parotid area in front of the right ear for more than 3 months". Through clinical examination, imaging examination, laboratory examination, and preoperative needle biopsy, the diagnosis of "right parotid moderately differentiated adenosquamous carcinoma complicated with IgG4-related disease" was considered. It was also considered that IgG4-related disease did not involve other organs before surgery, so no systemic hormone therapy was given before or after surgery. After surgery combined with postoperative radiotherapy, follow-up showed that neither the parotid tumor nor IgG4-related disease recurred. Conclusion:"IgG4-related disease complicated with moderately differentiated adenosquamous carcinoma"is a rare clinical disease. Both lack typical clinical manifestations and specific imaging features, and the diagnosis is mostly unclear before surgery. Pathological examination is of great significance in the diagnosis of the disease, while fine-needle aspiration has limited value in the diagnosis, which should attract the attention of clinicians. In addition, for patients with both diseases, individualized treatment plans should be formulated.
Humans
;
Parotid Neoplasms/pathology*
;
Male
;
Carcinoma, Adenosquamous/pathology*
;
Immunoglobulin G4-Related Disease/complications*
;
Parotid Gland/pathology*
;
Retrospective Studies
;
Aged
;
Biopsy, Fine-Needle
;
Immunoglobulin G
7.Pediatric salivary pleomorphic adenoma: report of 30 cases.
Yanzhen LI ; Xin NI ; Xuexi ZHANG ; Qiaoyin LIU ; Nian SUN ; Zhiyong LIU ; Xiaodan LI ; Jialu WANG ; Ge ZHANG ; Shengcai WANG
Journal of Clinical Otorhinolaryngology Head and Neck Surgery 2025;39(9):881-885
Objective:To summarize the clinical characteristics, diagnosis and treatment experience of salivary pleomorphic adenoma in children. Methods:Thirty patients with salivary pleomorphic adenomas treated in Beijing Childrens Hospital from January 2008 to December 2022 were retrospectively reviewed, including 11 boys and 19 girls, with the age ranging from 0.3 to 14.4 years(median age 10.4 years). Initial presentation, medical history, imaging workups, surgical approaches, complications, rates of recurrence were evaluated. Results:Major salivary gland lesions were most common(n=24, 80%); 53.3%(16 of 30) arising in the submandibular glands and 26.7%(8 of 30) in the parotid. Minor salivary gland lesions(n=6, 20%) were removed from the palate, tongue, face, trachea, nasopharynx, and upper mediastinumand. Preoperative imaging was reviewed in all patients and consisted of 26 ultrasound exams, 2 computerized tomography(CT) exams, and 15 magnetic resonance imaging(MRI) exams. Fine needle aspiration biopsy was performed in 12 patients. Surgical excision was performed in all patients. Postoperative complications included transient facial paresis(n=3), Pneumonia and pleural effusion(n=1). Average length of follow-up was 36.7 months; confirmed recurrence occurred in one patients. Conclusion:The symptoms of salivary gland pleomorphic adenoma in children are different according to the location of the tumor. The treatment is complete surgical resection, and a small amount of normal tissue around the tumor should be removed to reduce recurrence.
Humans
;
Male
;
Female
;
Child
;
Adenoma, Pleomorphic/diagnosis*
;
Adolescent
;
Retrospective Studies
;
Salivary Gland Neoplasms/diagnosis*
;
Child, Preschool
;
Infant
;
Neoplasm Recurrence, Local
8.Case report of robot-assisted resection of benign parotid gland tumor via hairline incision under facial nerve monitoring.
Xijun LIN ; Fang LIAO ; Xiaoming HUANG ; Faya LIANG
Journal of Clinical Otorhinolaryngology Head and Neck Surgery 2025;39(11):1053-1056
A 30-year-old female patient with a benign tumor in the superficial lobe of the left parotid gland underwent tumor resection via a 5 cm intra-hairline incision, using the da Vinci Xi surgical robot combined with the NIM-Response 3.0 facial nerve monitoring system. During the operation, facial nerve branches were located and protected through facial nerve monitoring, and the robotic arms were used for precise tumor dissection. Postoperatively, the facial nerve function, incision healing, and tumor recurrence were observed. duration of the procedure was 120 minutes, and the tumor(2.0 cm×1.5 cm) was completely resected. Postoperative pathological examination indicated a pleomorphic adenoma. During the 3-month postoperative follow-up, the patient's facial nerve function remained normal, no salivary fistula occurred, the incision was hidden within the hairline, no tumor recurrence was found in the ultrasound reexamination, and the patient was highly satisfied with the appearance. The surgical approach of robot-assisted resection of benign parotid gland tumor via a hairline incision under facial nerve monitoring has significant advantages in facial nerve protection and cosmetic effect, and is suitable for patients with benign parotid gland tumors meeting specific conditions.
Humans
;
Female
;
Adult
;
Parotid Neoplasms/surgery*
;
Facial Nerve
;
Robotic Surgical Procedures/methods*
;
Adenoma, Pleomorphic/surgery*
;
Parotid Gland/surgery*
;
Monitoring, Intraoperative
9.Lip and oral cancers in East Asia from 1990 to 2035: trends of disease burden and future projections.
Yitong LIU ; Ke ZHAO ; Xiaodong WANG
Journal of Southern Medical University 2025;45(7):1554-1562
OBJECTIVES:
To analyze the trends of disease burden of lip and oral cancers in East Asia from 1990 to 2021 and its future projections.
METHODS:
We used the Global Burden of Disease 2021 database to conduct a comprehensive analysis of disease burden data from China (including Taiwan Province of China), Japan, Republic of Korea, Democratic People's Republic of Korea and Mongolia. The data were stratified by age, gender and major risk factors, and a Bayesian age-period-cohort model was employed to predict the future trends.
RESULTS:
From 1990 to 2021, the burden of lip and oral cancers in East Asian countries exhibited a steady increase. Taiwan Province of China experienced the most significant increases in incidence, prevalence, mortality, and disability-adjusted life years (DALYs), while Mongolia saw a decline in both mortality and DALYs. In 2021, Taiwan Province of China reported the highest rates of lip and oral cancer incidence (27.50 per 100 000), prevalence (137.92 per 100 000), mortality (9.59 per 100 000), and DALYs (292.07 person-years per 100 000), particularly among male and elderly populations. Tobacco use and alcohol consumption significantly exacerbated the disease burden in Taiwan Province of China and Japan. Future projections indicate that the incidence and prevalence of lip and oral cancer in China (excluding Taiwan Province of China) will continue to rise, while their mortality rates are expected to decline in most regions, except for Taiwan Province of China and Democratic People's Republic of Korea.
CONCLUSIONS
By the year 2035, the disease burden of lip and oral cancers in East Asia is expected to continue to increase, especially in Taiwan Province of China. To address this challenge, it is essential to implement effective measures to control major risk factors, promote early screening, and ensure equitable distribution of healthcare resources.
Humans
;
Mouth Neoplasms/epidemiology*
;
Incidence
;
Lip Neoplasms/epidemiology*
;
Asia, Eastern/epidemiology*
;
Male
;
Disability-Adjusted Life Years
;
Prevalence
;
Female
;
Forecasting
;
Risk Factors
;
Cost of Illness
;
Middle Aged
;
Global Burden of Disease
;
Aged
;
Bayes Theorem
10.Cancer-Associated Fibroblasts Interact with Schwann Cells for Tumor Perineural Invasion by Oral Squamous Cell Carcinoma.
Xinwen ZHANG ; Yijia HE ; Shixin XIE ; Yuxian SONG ; Xiaofeng HUANG ; Qingang HU ; Yanhong NI ; Yi WANG ; Yong FU ; Liang DING
Neuroscience Bulletin 2025;41(6):1003-1020
Perineural invasion (PNI) by tumor cells is a key phenotype of highly-invasive oral squamous cell carcinoma (OSCC). Since Schwann cells (SCs) and fibroblasts maintain the physiological homeostasis of the peripheral nervous system, and we have focused on cancer-associated fibroblasts (CAFs) for decades, it's imperative to elucidate the impact of CAFs on SCs in PNI+ OSCCs. We describe a disease progression-driven shift of PNI- towards PNI+ during the progression of early-stage OSCC (31%, n = 125) to late-stage OSCC (53%, n = 97), characterized by abundant CAFs and nerve demyelination. CAFs inhibited SC proliferation/migration and reduced neurotrophic factors and myelin in vitro, and this involved up-regulated ER stress and decreased MAPK signals. Moreover, CAFs also aggravated the paralysis of the hind limb and PNI in vivo. Unexpectedly, leukemia inhibitory factor (LIF) was exclusively expressed on CAFs and up-regulated in metastatic OSCC. The LIF inhibitor EC330 restored CAF-induced SC inactivation. Thus, OSCC-derived CAFs inactivate SCs to aggravate nerve injury and PNI development.
Schwann Cells/metabolism*
;
Mouth Neoplasms/metabolism*
;
Humans
;
Cancer-Associated Fibroblasts/metabolism*
;
Animals
;
Carcinoma, Squamous Cell/metabolism*
;
Neoplasm Invasiveness/pathology*
;
Male
;
Female
;
Mice
;
Cell Movement/physiology*
;
Cell Proliferation/physiology*
;
Cell Line, Tumor
;
Leukemia Inhibitory Factor/metabolism*
;
Middle Aged

Result Analysis
Print
Save
E-mail